Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages

Invivyd, Inc. (NASDAQ:IVVD) has received a consensus recommendation of “Hold” from the six analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $8.00.

A number of equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price target on shares of Invivyd in a research report on Thursday, February 26th.

Insider Transactions at Invivyd

In other news, insider Julie Green sold 20,964 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the sale, the insider directly owned 107,717 shares of the company’s stock, valued at $170,192.86. This trade represents a 16.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Robert D. Allen III sold 19,392 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $30,639.36. Following the sale, the insider directly owned 114,487 shares of the company’s stock, valued at approximately $180,889.46. This represents a 14.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 227,172 shares of company stock worth $354,534. Company insiders own 25.40% of the company’s stock.

Institutional Trading of Invivyd

A number of large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC grew its position in shares of Invivyd by 28.2% during the 4th quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock valued at $80,870,000 after acquiring an additional 7,160,065 shares during the period. Perceptive Advisors LLC purchased a new stake in shares of Invivyd during the 4th quarter worth approximately $53,809,000. BVF Inc. IL bought a new stake in shares of Invivyd in the 4th quarter worth approximately $48,227,000. RA Capital Management L.P. bought a new stake in shares of Invivyd in the 3rd quarter worth approximately $18,831,000. Finally, ADAR1 Capital Management LLC purchased a new position in Invivyd in the third quarter valued at approximately $8,108,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Stock Performance

Shares of IVVD stock opened at $1.28 on Tuesday. The company has a market capitalization of $361.73 million, a price-to-earnings ratio of -4.00 and a beta of 0.73. Invivyd has a 52-week low of $0.46 and a 52-week high of $3.07. The company has a 50-day simple moving average of $1.65 and a two-hundred day simple moving average of $1.90.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.